Want to see ENTX full AI Analyst Report?
Top Page
Entera Bio
(NASDAQ:ENTX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$3.50
▲(70.73% Upside)
Action:Reiterated
Date:07/29/26
The score is held down primarily by weak financial performance (no revenue, persistent losses, and significantly deteriorated cash burn), which increases dependence on external funding. Offsetting this, technicals show strong upward price trends versus all key moving averages, and corporate events provide meaningful funding for Phase 3 progress, albeit with notable dilution risk. Valuation remains unattractive due to the negative P/E and lack of dividend support.
Positive Factors
Low leverage / balance sheet flexibility
Very low debt-to-equity (~0.04) materially reduces financial distress risk and preserves borrowing capacity. This structural strength gives management flexibility to fund R&D or partnerships without high interest burden, supporting sustained clinical execution over months.
Negative Factors
Deteriorating cash generation
Sustained negative operating cash flow (~-$21.9M TTM) and FCF (~-$22.0M) indicate cash consumption is substantive and worsening. This structural cash drain increases dependency on external financing and constrains discretionary R&D or commercial investments absent further capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet flexibility
Very low debt-to-equity (~0.04) materially reduces financial distress risk and preserves borrowing capacity. This structural strength gives management flexibility to fund R&D or partnerships without high interest burden, supporting sustained clinical execution over months.
Read all positive factors
Entera Bio (ENTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$147.38M
Dividend YieldN/A
Average Volume (3M)123.78K
Price to Earnings (P/E)―
Beta (1Y)0.34
Revenue Growth-100.00%
EPS Growth-2.09%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding49,290,234
10 Day Avg. Volume240,874
30 Day Avg. Volume123,776
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside339.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$54.58M
Entera Bio Business Overview & Revenue Model
Company Description
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary exp...
How the Company Makes Money
null...
Entera Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 42.00K | 181.00K | 0.00 | 134.00K | 571.00K |
| Gross Profit | -15.00K | 0.00 | 9.00K | -56.00K | -31.00K | 198.00K |
| EBITDA | -12.35M | -11.41M | -9.48M | -8.80M | -12.87M | -12.16M |
| Net Income | -12.38M | -11.44M | -9.54M | -8.89M | -13.07M | -12.19M |
Balance Sheet | ||||||
| Total Assets | 13.13M | 15.99M | 9.39M | 11.77M | 13.13M | 25.99M |
| Cash, Cash Equivalents and Short-Term Investments | 4.14M | 7.11M | 8.66M | 11.02M | 12.31M | 24.89M |
| Total Debt | 448.00K | 490.00K | 272.00K | 390.00K | 91.00K | 302.00K |
| Total Liabilities | 2.44M | 2.89M | 1.31M | 1.38M | 1.37M | 3.42M |
| Stockholders Equity | 10.69M | 13.10M | 8.08M | 10.39M | 11.75M | 22.57M |
Cash Flow | ||||||
| Free Cash Flow | -9.59M | -7.48M | -6.82M | -7.33M | -12.55M | -9.08M |
| Operating Cash Flow | -9.49M | -7.37M | -6.82M | -7.31M | -12.50M | -9.06M |
| Investing Cash Flow | -105.31K | -107.00K | -3.00K | -17.00K | -102.00K | -17.00K |
| Financing Cash Flow | 1.27M | 13.71M | 4.48M | 6.04M | 13.00K | 25.38M |
Entera Bio Technical Analysis
Positive
2.05
Price Trends
1.71
Positive
1.46
Positive
1.71
Positive
Market Momentum
0.41
Negative
64.49
Neutral
46.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTX, the sentiment is Positive. The current price of 2.05 is below the 20-day moving average (MA) of 2.25, above the 50-day MA of 1.71, and above the 200-day MA of 1.71, indicating a bullish trend. The MACD of 0.41 indicates Negative momentum. The RSI at 64.49 is Neutral, neither overbought nor oversold. The STOCH value of 46.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENTX.
Entera Bio Risk Analysis
Entera Bio disclosed 2 risk factors in its most recent earnings report. Entera Bio reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Security, political and economic instability in the Middle East may harm our business. Q1, 2026
Entera Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $147.38M | -11.35 | -87.97% | ― | -100.00% | -2.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $132.12M | -2.46 | 107.73% | ― | ― | 36.33% | |
46 Neutral | $47.62M | -0.67 | -99.87% | ― | ― | 8.93% | |
44 Neutral | $139.10M | -5.85 | -61.43% | ― | -100.00% | 18.25% | |
44 Neutral | $64.40M | -0.57 | -59.06% | ― | ― | 49.00% |
* Healthcare Sector Average
ENTX
Entera Bio
2.96
0.94
46.53%
ATYR
aTyr Pharma
0.49
-4.73
-90.57%
NRXP
NRX Pharmaceuticals
3.24
0.60
22.73%
EQ
Equillium
2.20
1.60
269.13%
PLRX
Pliant Therapeutics
1.04
-0.69
-39.88%
Entera Bio Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Entera Bio Raises $275M in Strategic Private Placement
Positive
Jul 28, 2026
On July 26, 2026, Entera Bio entered into a securities purchase agreement with institutional and accredited investors for a $275 million private placement of 134,803,910 ordinary shares and pre-funded warrants at $2.04 per share, which closed on J...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Entera Bio Expands Share Authorization and Equity Plans
Positive
Jul 17, 2026
At its 2026 Annual Meeting of Shareholders held on July 14, 2026, Entera Bio’s investors approved an amendment to the company’s Articles of Association, increasing authorized ordinary shares from 140,010,000 to 350,000,000. The move, a...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Entera Bio Highlights Q1 2026 Progress and Financing
Positive
May 8, 2026
Entera Bio reported first-quarter 2026 results on May 8, 2026, highlighting progress across its oral peptide pipeline, led by EB613, an oral anabolic tablet for postmenopausal osteoporosis. In March 2026 the company submitted a streamlined Phase 3...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.